U.S. Online Retail and Ecommerce Stock News

NYSE:OPY
NYSE:OPYCapital Markets

Is It Too Late To Consider Oppenheimer Holdings (OPY) After A 69% One-Year Rally?

Investors may be wondering whether Oppenheimer Holdings at around US$99 a share still offers value, or if most of the opportunity has already been priced in. The stock has been volatile recently, with an 11.3% pullback over the last 7 days alongside a 9.3% gain over 30 days, and returns of 36.8% year to date and 69.4% over the past year. Recent headlines around capital markets activity and trading conditions have kept investor attention on brokers and financial services stocks, including...
NYSE:HPQ
NYSE:HPQTech

Has The Recent Rebound In HP (HPQ) Created A Fresh Opportunity For Investors

If you are wondering whether HP's current share price reflects its real value, you are not alone. This article walks through what the latest data says about where the stock stands today. HP shares last closed at US$21.15, with recent returns of 7.2% over 7 days and 8.4% over 30 days, but a 4.4% decline year to date and a 13.3% decline over 1 year. This frames an important question about whether the recent rebound changes the risk and reward trade off. Recent news coverage has focused on HP's...
NasdaqGS:WFRD
NasdaqGS:WFRDEnergy Services

Is It Too Late To Consider Weatherford International (WFRD) After Its 152% One Year Surge?

If you are wondering whether Weatherford International at around US$108.61 is still offering value after its run, this breakdown will help you see what the current price really reflects. The stock has seen a 14.0% gain over the last 30 days and a 34.3% return year to date, while the 1 year return sits at 151.7% despite a 1.5% decline over the past week. Recent news around Weatherford International has focused on its position within the broader energy services sector and how investors are...
NasdaqGS:VRSN
NasdaqGS:VRSNIT

VeriSign (VRSN) Valuation Check After Strong Q1 Results New Guidance And Confirmed Dividend

Why VeriSign’s latest earnings, guidance and dividend matter for investors VeriSign (VRSN) has drawn fresh attention after reporting first quarter 2026 results alongside updated full year guidance and a Board approved cash dividend, giving investors several new data points to assess. See our latest analysis for VeriSign. The earnings beat, fresh 2026 guidance and the approved US$0.81 dividend have coincided with firmer sentiment, with a 30 day share price return of 6.13% and a 14.65% year to...
NasdaqCM:SAFX
NasdaqCM:SAFXOil and Gas

Assessing XCF Global (SAFX) Valuation After Reno Restart, Twain Forbearance Deal And New Business Combination

XCF Global (SAFX) has drawn fresh attention after a series of updates, including a Q1 2026 operational briefing, a business combination agreement, a forbearance deal with lender Twain, and a sector conference appearance. See our latest analysis for XCF Global. Recent updates around the Reno facility restart, the business combination agreement, and the Twain forbearance deal have coincided with a sharp shift in sentiment, with a 90 day share price return of 166.1% but a 3 year total...
NasdaqGS:UTHR
NasdaqGS:UTHRBiotechs

Will Softer Q1 2026 Results Test How United Therapeutics (UTHR) Funds Its Innovation Ambitions?

United Therapeutics Corporation has already reported first-quarter 2026 results, with sales of US$781.5 million and net income of US$274.9 million, both lower than the same period last year and below analyst expectations. The earnings shortfall contrasts with earlier optimism driven by positive ralinepag Phase 3 data and pipeline milestones in pulmonary disease and organ technologies, sharpening investor focus on how reliably current products can fund future innovation. Against this backdrop...
NasdaqGS:NUVL
NasdaqGS:NUVLBiotechs

Guardant Diagnostic Alliance Could Be A Game Changer For Nuvalent’s Targeted Oncology Strategy (NUVL)

In April 2026, Guardant Health announced a multi-year collaboration with Nuvalent to use its Guardant Infinity platform’s tissue and liquid biopsy tests in supporting Nuvalent’s global oncology trials and potential commercialization efforts. This alliance highlights how pairing Nuvalent’s kinase-targeted cancer therapies with Guardant’s precision diagnostics could tighten patient selection, streamline regulatory pathways, and strengthen future companion diagnostic strategies. Next, we’ll...
NasdaqGM:TVTX
NasdaqGM:TVTXBiotechs

Travere Therapeutics (TVTX) Heads Into Q1 2026 With Sharply Narrowed Trailing Losses Testing Bull Case

Q1 2026 earnings snapshot sets up margins story for Travere Therapeutics (TVTX) Travere Therapeutics (TVTX) heads into its Q1 2026 update with recent quarterly revenue of US$129.7 million in Q4 2025 and basic EPS of US$0.29 in Q3 2025 giving way to a loss of US$0.24 per share in Q4, alongside trailing 12 month revenue of US$490.7 million and a net loss of US$50.3 million. Over the past year, revenue has moved from US$233.2 million on a trailing 12 month basis in Q4 2024 to US$490.7 million in...
NYSE:SPB
NYSE:SPBHousehold Products

Spectrum Brands And Oaktree Deal Refocuses Value On Home And Personal Care

Spectrum Brands Holdings (NYSE:SPB) has entered into a partnership with Oaktree Capital Management focused on its Home and Personal Care business. The transaction brings new investment into the segment and marks another step in Spectrum Brands' plan to separate this business from the rest of the company. The move is intended to reshape how Spectrum Brands allocates resources across its portfolio and could influence how investors view the stock. At a share price of $82.38 and with a return...
NYSE:PRG
NYSE:PRGConsumer Finance

PROG Holdings (PRG) Is Up 23.0% After Raising 2026 Outlook On Transformation Progress – What's Changed

In late April 2026, PROG Holdings reported first-quarter 2026 results showing revenue of US$742.67 million and net income of US$36.05 million, alongside higher earnings per share from continuing operations compared with a year earlier. The company also raised its full-year 2026 guidance for revenues and earnings from continuing operations, underscoring management’s confidence in its ongoing business transformation beyond Progressive Leasing, including Four Technologies and other newer...
NYSE:AMCR
NYSE:AMCRPackaging

Amcor Portfolio Shift Puts Waste And Closures Sales Under Investor Spotlight

Amcor (NYSE:AMCR) has entered exclusive talks to sell its ESE World waste management unit. The company has also agreed to sell two North American beverage closure plants. Together, these asset moves point to a reshaping of Amcor’s portfolio toward its core packaging operations. For investors watching NYSE:AMCR, these portfolio changes arrive after a stretch of weaker share performance, with the stock down 10.5% year to date and 13.1% over the past year, at a recent price of $37.64. In that...
NYSE:KN
NYSE:KNElectronic

Diamond Hill Backs Knowles Portfolio Reset As Profitability Story Builds

Diamond Hill Capital has initiated a new position in Knowles (NYSE:KN), citing confidence in the reshaped portfolio and growth potential. The move highlights fresh institutional interest in the company beyond recent earnings, guidance and valuation discussions. Knowles shares last closed at $33.28, with the stock up 9.7% over the past week and 106.1% over the past year. For investors watching Knowles, Diamond Hill Capital’s new stake puts a spotlight on how the company’s portfolio reset is...
NasdaqGM:KALV
NasdaqGM:KALVBiotechs

Chiesi Deal Shapes KalVista Shareholder Outlook And Valuation Potential

Chiesi Farmaceutici S.p.A. has entered into a definitive agreement to acquire KalVista Pharmaceuticals (NasdaqGM:KALV). The deal includes a tender offer followed by a merger process, with completion subject to specified closing conditions. Responsibility for EKTERLY®, a treatment for hereditary angioedema (HAE), is set to move from KalVista to Chiesi once the transaction is finalized. KalVista focuses on treatments for hereditary angioedema, and EKTERLY® is a key product in that portfolio...
NasdaqGS:META
NasdaqGS:METAInteractive Media and Services

Is It Time To Reassess Meta Platforms (META) After Its Recent Share Price Pullback?

Wondering whether Meta Platforms at around US$604.96 is still a compelling stock or if most of the value is already on the table? This article breaks down what the current price may be implying. The stock has seen a 9.9% decline over the last 7 days, a 5.3% gain over the last 30 days, a 7.0% decline year to date, and a 3.3% return over the last year, with longer term returns of 161.3% over 3 years and 98.9% over 5 years. Recent headlines have focused on Meta Platforms' long term share price...
NYSE:ARES
NYSE:ARESCapital Markets

Is It Too Late To Reassess Ares Management (ARES) After Its Recent Price Jump?

Evaluating whether Ares Management is attractively priced at the moment, or if the stock already reflects its potential, begins with understanding how its current market value compares with its fundamentals. The stock recently closed at US$122.96, with a 7 day return of 8.8%, a 30 day return of 20.0%, a year to date return showing a 26.1% decline, a 1 year return showing a 20.4% decline, a 3 year return of 66.9%, and a 5 year return of 173.5%. Recent headlines around Ares Management have...
NasdaqGS:NTNX
NasdaqGS:NTNXSoftware

Nutanix And Leostream Team Up On GPU Remote Access And HPC Workloads

Leostream Corporation and Nutanix (NasdaqGS:NTNX) have partnered to deliver unified remote access solutions for high performance computing environments. The collaboration brings together Nutanix infrastructure with Leostream's access platform to support scalable GPU workloads across cloud and hybrid cloud deployments. The new offering focuses on certified integrations and deeper interoperability for enterprises running distributed, compute intensive applications. Nutanix focuses on hybrid...
NYSE:KOF
NYSE:KOFBeverage

Assessing Coca-Cola FEMSA (NYSE:KOF) Valuation After Recent Share Price Strength

Coca-Cola FEMSA. de: recent performance snapshot Coca-Cola FEMSA. de (KOF) has drawn investor interest after recent trading, with the stock last closing at US$106.58 and showing positive returns over the past week, month, and year. See our latest analysis for Coca-Cola FEMSA. de. The recent 5.3% 1 day share price return and 7.9% 30 day share price return sit alongside a 17.4% 1 year total shareholder return and 165.4% 5 year total shareholder return. This suggests that momentum has been...
NYSE:WH
NYSE:WHHospitality

A Look At Wyndham Hotels & Resorts (WH) Valuation After Recent Share Price Pullback

Why Wyndham Hotels & Resorts Stock Is On Watch Wyndham Hotels & Resorts (WH) has delivered mixed return patterns, with the stock up about 7% over the past 3 months yet showing a small decline over the past year, which may prompt closer investor attention. See our latest analysis for Wyndham Hotels & Resorts. The recent pullback, including a 7 day share price return of a 5.9% decline and a 30 day share price return of a 2.2% decline, contrasts with a 6.8% gain over 3 months and a 26.5% three...
NYSE:AAMI
NYSE:AAMICapital Markets

A Look At Acadian Asset Management (AAMI) Valuation After Record First Quarter And Strong Share Price Gains

Acadian Asset Management (AAMI) is in focus after reporting record first quarter results, including higher revenue, profit and assets under management, alongside continued dividends, buybacks and investment in AI driven research capabilities. See our latest analysis for Acadian Asset Management. The record first quarter has been met with strong momentum, with the share price up 23.63% over the past month and a 136.79% total shareholder return over the past year, suggesting investors are...
NasdaqGS:SHC
NasdaqGS:SHCLife Sciences

Sotera Health (SHC) Margin Improvement To 6.7% Tests Bullish Profitability Narrative

Sotera Health (SHC) has just opened Q1 2026 reporting with trailing numbers that show total revenue of about US$1.2b over the last 12 months and basic EPS of US$0.27, alongside year over year earnings growth of 75.8%. Over the past reported quarters, revenue has ranged from US$254.5 million in Q1 2025 to US$311.3 million in Q3 2025, while quarterly basic EPS moved from a loss of US$0.05 in Q1 2025 to US$0.17 in Q3 2025, illustrating improving profit conversion as trailing net margin sits at...
NYSE:EQH
NYSE:EQHDiversified Financial

Equitable Holdings (EQH) Earnings Volatility And TTM Loss Challenge Bullish Narratives

Equitable Holdings (EQH) has just reported its Q1 2026 results with recent quarterly revenue figures ranging from US$1.4 billion to US$4.6 billion and basic EPS swinging between a loss of US$4.47 and a profit of US$0.71. On a trailing 12 month basis, EPS was US$4.83 in Q4 2024 before moving to a loss of US$4.83 by Q4 2025. Over the past year, the company has seen revenue move between US$10.8 billion and US$15.1 billion on a trailing 12 month view and net income shift from a profit of US$1.2...